anti-NF-kB p65 Antibody from antibodies-online

Supplier Page

Supplier Page from
antibodies-online for
anti-NF-kB p65 Antibody

Description

Product Characteristics:
NF-kappa-B is a ubiquitous transcription factor involved in several biological processes. It is held in the cytoplasm in an inactive state by specific inhibitors. Upon degradation of the inhibitor, NF-kappa-B moves to the nucleus and activates transcription of specific genes. NF-kappa-B is composed of NFKB1 or NFKB2 bound to either REL, RELA, or RELB. The most abundant form of NF-kappa-B is NFKB1 complexed with the product of this gene, RELA. Four transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2011].

Subcellular location: Cytoplasm, Nucleus

Synonyms: NFkB-p65Thr435, RELAphospho T435, NFKBp65, NF-Bp65, p65 NF kappaB, p65 NFkB, NFKBp65, RELA, Transcription Factor p65, v rel avian reticuloendotheliosis viral oncogene homolog A nuclear factor of kappa light polypeptide gene enhancer in B cells 3 p65, V Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A, v rel reticuloendotheliosis viral oncogene homolog A avian, v-rel reticuloendotheliosis viral oncogene homolog A, p65NFKB, Avian reticuloendotheliosis viral v rel oncogene homolog A, MGC131774, NFKB 3, NFKB3, Nuclear Factor NF Kappa B p65 Subunit, Nuclear factor of kappa light polypeptide gene enhancer in B cells 3, Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B Cells.

Target Information: NF-kappa-B is a ubiquitous transcription factor involved in several biological processes. It is held in the cytoplasm in an inactive state by specific inhibitors. Upon degradation of the inhibitor, NF-kappa-B moves to the nucleus and activates transcription of specific genes. NF-kappa-B is composed of NFKB1 or NFKB2 bound to either REL, RELA, or RELB. The most abundant form of NF-kappa-B is NFKB1 complexed with the product of this gene, RELA. Four transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2011]